M
10.17
-0.36 (-3.42%)
| Previous Close | 10.53 |
| Open | 10.55 |
| Volume | 1,253,009 |
| Avg. Volume (3M) | 611,683 |
| Market Cap | 941,307,136 |
| Price / Earnings (Forward) | 1.61 |
| Price / Sales | 10.41 |
| Price / Book | 225.31 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2026 |
| Operating Margin (TTM) | -2,159.71% |
| Diluted EPS (TTM) | -2.31 |
| Quarterly Revenue Growth (YOY) | 176.30% |
| Total Debt/Equity (MRQ) | 244.35% |
| Current Ratio (MRQ) | 1.52 |
| Operating Cash Flow (TTM) | -104.58 M |
| Levered Free Cash Flow (TTM) | -53.25 M |
| Return on Assets (TTM) | -37.28% |
| Return on Equity (TTM) | -216.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | MeiraGTx Holdings plc | Mixed | Bullish |
AIStockmoo Score
-0.6
| Analyst Consensus | 2.0 |
| Insider Activity | -3.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | -0.60 |
|
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 24.27% |
| % Held by Institutions | 60.04% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |